BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $125,658 | -15.4% | 20,978 | 0.0% | 0.00% | -33.3% |
| Q3 2023 | $148,524 | +11.2% | 20,978 | +10.6% | 0.01% | +20.0% |
| Q2 2023 | $133,576 | -15.6% | 18,974 | 0.0% | 0.01% | -16.7% |
| Q1 2023 | $158,243 | +71503.2% | 18,974 | -1.4% | 0.01% | -33.3% |
| Q4 2022 | $221 | -99.9% | 19,237 | -1.4% | 0.01% | -18.2% |
| Q3 2022 | $246,000 | +20.0% | 19,515 | +0.6% | 0.01% | +22.2% |
| Q2 2022 | $205,000 | -30.7% | 19,408 | +6.6% | 0.01% | -10.0% |
| Q1 2022 | $296,000 | +17.5% | 18,208 | 0.0% | 0.01% | +25.0% |
| Q4 2021 | $252,000 | – | 18,208 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |